SCHEMBL367947

SCHEMBL367947

NC(=O)c1ccc(C(=O)N2CCCCC2)cc1

nearest known ligand 0.80

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 9/20 0.80
ALDH1A1 P00352 4/20 0.80
CA12 O43570 2/20 0.64
CA1 P00915 2/20 0.64
CA2 P00918 2/20 0.64
CA7 P43166 2/20 0.64
CA9 Q16790 2/20 0.64
CA14 Q9ULX7 2/20 0.64
MEN1 O00255 1/20 0.61
TSHR P16473 1/20 0.61
KMT2A Q03164 1/20 0.61
MAOA P21397 1/20 0.60
MAPK1 P28482 1/20 0.59
MLYCD O95822 2/20 0.58
USP2 O75604 1/20 0.58
MAPT P10636 1/20 0.57
LMNA P02545 1/20 0.57
MBTD1 Q05BQ5 3/20 0.56
L3MBTL3 Q96JM7 3/20 0.56
L3MBTL1 Q9Y468 2/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL170330 1.00 HPGD (0.80) HPGDALDH1A1CA12CA1CA2
SCHEMBL1194042 1.00 HPGD (0.80) HPGDALDH1A1CA12CA1CA2
SCHEMBL367513 1.00 HPGD (0.80) HPGDALDH1A1CA12CA1CA2
SCHEMBL367607 1.00 HPGD (0.80) HPGDALDH1A1CA12CA1CA2
SCHEMBL1160398 1.00 HPGD (0.80) HPGDALDH1A1CA12CA1CA2
Terephthalamide SCHEMBL1160108 1.00 HPGD (0.80) HPGDALDH1A1CA12CA1CA2
Terephthalamide SCHEMBL13724808 1.00 HPGD (0.80) HPGDALDH1A1CA12CA1CA2
SCHEMBL11857269 1.00 HPGD (0.80) HPGDALDH1A1CA12CA1CA2
SCHEMBL4560822 1.00 HPGD (0.80) HPGDALDH1A1CA12CA1CA2
SCHEMBL1159865 1.00 HPGD (0.80) HPGDALDH1A1CA12CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1628972-B1 INDAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS SANOFI AVENTIS DEUTSCHLAND (DE) 2009-04-22 EP claimed
EP-1628972-A1 INDAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS Sanofi-Aventis Deutschland GmbH (DE) 2006-03-01 EP claimed
US-20040235824-A1 Indazole-derivatives as factor Xa inhibitors AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2004-11-25 US claimed
WO-2004101556-A1 INDAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2004-11-25 WO claimed
EP-1479675-A1 Indazole-derivatives as factor Xa inhibitors Aventis Pharma Deutschland GmbH (DE) 2004-11-24 EP claimed
EP-3860975-B1 MODULATORS OF HEMOGLOBIN FOR THE TREATMENT OF SICKLE CELL DISEASE GLOBAL BLOOD THERAPEUTICS INC (US) 2023-10-18 EP disclosed
US-20230079764-A1 Polymerization Process DUPONT POLYMERS INC (US) 2023-03-16 US disclosed
CN-111183174-B Glass fiber reinforced resin molded article 日东纺绩株式会社 2022-10-04 CN disclosed
CN-114144473-A Polyamide resin composition and molded article obtained by molding same 东丽株式会社 2022-03-04 CN disclosed
US-11254082-B2 Multi-layer tube UBE INDUSTRIES, LTD. (JP) 2022-02-22 US disclosed
CN-113817157-A Semi-aromatic polyamide polycondensation catalyst and preparation method thereof 四川大学 2021-12-21 CN disclosed
CN-113150269-A Semi-aromatic polyamide copolymer and preparation thereof 上海庚彩新材料科技有限公司 2021-07-23 CN disclosed
US-20120016077-A1 POLYAMIDE RESIN, POLYAMIDE RESIN COMPOSITION, AND MOLDED ARTICLE COMPRISING SAME TORAY INDUSTRIES INC. (JP) 2012-01-19 US disclosed
EP-1628972-B1 INDAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS SANOFI AVENTIS DEUTSCHLAND (DE) 2009-04-22 EP disclosed
US-7365088-B2 Indazole-derivatives as factor Xa inhibitors SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2008-04-29 US disclosed
EP-1628972-A1 INDAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS Sanofi-Aventis Deutschland GmbH (DE) 2006-03-01 EP disclosed
US-20040235824-A1 Indazole-derivatives as factor Xa inhibitors AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2004-11-25 US disclosed
WO-2004101556-A1 INDAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2004-11-25 WO disclosed
EP-1479675-A1 Indazole-derivatives as factor Xa inhibitors Aventis Pharma Deutschland GmbH (DE) 2004-11-24 EP disclosed
CN-1336919-A Phenylphenanthridines with PDE-IV inhibiting activity BYK GULDEN LOMBERG CHEM FAB (DE) 2002-02-20 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040235824-A1 Indazole-derivatives as factor Xa inhibitors F11, F12, F5 HPGD 678/4885ALDH1A1 1259/4885CA12 4425/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.